148 related articles for article (PubMed ID: 2491747)
1. Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture.
Brock N
Cancer Res; 1989 Jan; 49(1):1-7. PubMed ID: 2491747
[TBL] [Abstract][Full Text] [Related]
2. Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.
Brock N
J Cancer Res Clin Oncol; 1986; 111(1):1-12. PubMed ID: 3949846
[TBL] [Abstract][Full Text] [Related]
3. Basis and new developments in the field of oxazaphosphorines.
Brock N; Hilgard P; Peukert M; Pohl J; Sindermann H
Cancer Invest; 1988; 6(5):513-32. PubMed ID: 3063337
[TBL] [Abstract][Full Text] [Related]
4. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Brock N; Pohl J
IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
[TBL] [Abstract][Full Text] [Related]
5. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
Brock N; Stekar J; Pohl J; Niemeyer U; Scheffler G
Arzneimittelforschung; 1979; 29(4):659-61. PubMed ID: 114192
[TBL] [Abstract][Full Text] [Related]
6. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
[TBL] [Abstract][Full Text] [Related]
7. Effects of oxazaphosphorine cytostatics on granuloid progenitor cell (CFUc) proliferation in mice.
Semont H; Hecquet C; Adolphe M; Deysson G
Exp Hematol; 1982 Oct; 10(9):782-8. PubMed ID: 7173344
[TBL] [Abstract][Full Text] [Related]
8. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
Brock N; Pohl J; Stekar J
J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
[TBL] [Abstract][Full Text] [Related]
9. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
Blomgren H; Hallström M
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
[TBL] [Abstract][Full Text] [Related]
10. Effect of three alkylating antimitotic agents and their metabolites on in vitro monogranulocytic colony forming cells from mouse bone marrow.
Semont H; Hecquet C; Adolphe M; Deysson G
Arzneimittelforschung; 1981; 31(3):470-3. PubMed ID: 7194671
[TBL] [Abstract][Full Text] [Related]
11. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
Brock N
Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
Burkert H; Schnitker J; Fichtner E
MMW Munch Med Wochenschr; 1979 Jun; 121(22):760-2. PubMed ID: 112422
[TBL] [Abstract][Full Text] [Related]
14. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
Kunze E; Köhnecke B; Engelhardt W; Steinröder H; Brock N; Pohl J
Urol Int; 1984; 39(2):61-7. PubMed ID: 6426112
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
16. An overview of cyclophosphamide and ifosfamide pharmacology.
Fleming RA
Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
19. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
Brock N; Pohl J; Stekar J; Scheef W
Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]